
Align Technology (ALGN) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
979.3M
Gross Profit
680.1M
69.45%
Operating Income
135.3M
13.81%
Net Income
93.2M
9.52%
EPS (Diluted)
$1.27
Balance Sheet Metrics
Total Assets
6.1B
Total Liabilities
2.3B
Shareholders Equity
3.8B
Debt to Equity
0.61
Cash Flow Metrics
Operating Cash Flow
139.2M
Free Cash Flow
27.4M
Revenue & Profitability Trend
Align Technology Income Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Revenue | 4.0B | 3.9B | 3.7B | 4.0B | 2.5B |
Cost of Goods Sold | 1.2B | 1.2B | 1.1B | 1.0B | 708.7M |
Gross Profit | 2.8B | 2.7B | 2.6B | 2.9B | 1.8B |
Gross Margin % | 70.0% | 70.1% | 70.5% | 74.3% | 71.3% |
Operating Expenses | |||||
Research & Development | 364.2M | 346.8M | 305.3M | 250.3M | 175.3M |
Selling, General & Administrative | 1.8B | 1.7B | 1.7B | 1.7B | 1.2B |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 2.1B | 2.1B | 2.0B | 2.0B | 1.4B |
Operating Income | 671.8M | 656.7M | 654.0M | 976.4M | 387.2M |
Operating Margin % | 16.8% | 17.0% | 17.5% | 24.7% | 15.7% |
Non-Operating Items | |||||
Interest Income | 20.2M | 17.3M | 5.4M | 3.1M | 3.1M |
Interest Expense | - | - | - | - | - |
Other Non-Operating Income | -83.0M | -32.7M | -60.4M | 32.9M | -11.3M |
Pre-tax Income | 609.0M | 641.2M | 599.1M | 1.0B | 378.9M |
Income Tax | 187.6M | 196.2M | 237.5M | 240.4M | -1.4B |
Effective Tax Rate % | 30.8% | 30.6% | 39.6% | 23.7% | -368.6% |
Net Income | 421.4M | 445.1M | 361.6M | 772.0M | 1.8B |
Net Margin % | 10.5% | 11.5% | 9.7% | 19.5% | 71.8% |
Key Metrics | |||||
EBITDA | 880.9M | 812.4M | 791.3M | 1.1B | 480.7M |
EPS (Basic) | $5.63 | $5.82 | $4.62 | $9.78 | $22.55 |
EPS (Diluted) | $5.62 | $5.81 | $4.61 | $9.69 | $22.41 |
Basic Shares Outstanding | 74877000 | 76426000 | 78190000 | 78917000 | 78760000 |
Diluted Shares Outstanding | 74877000 | 76426000 | 78190000 | 78917000 | 78760000 |
Income Statement Trend
Align Technology Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 1.0B | 937.4M | 942.0M | 1.1B | 960.8M |
Short-term Investments | 0 | 35.3M | 57.5M | 72.0M | 0 |
Accounts Receivable | 995.7M | 903.4M | 859.7M | 897.2M | 657.7M |
Inventory | 254.3M | 296.9M | 338.8M | 230.2M | 139.2M |
Other Current Assets | 81.6M | 77.3M | 16.8M | 31.5M | 61.7M |
Total Current Assets | 2.5B | 2.4B | 2.4B | 2.5B | 1.8B |
Non-Current Assets | |||||
Property, Plant & Equipment | 985.2M | 821.8M | 702.7M | 574.1M | 454.6M |
Goodwill | 988.7M | 921.2M | 910.8M | 946.8M | 1.0B |
Intangible Assets | 103.5M | 82.1M | 95.7M | 109.7M | 130.1M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 1.8B | 1.7B | 1.6B | 1.6B | 1.6B |
Total Non-Current Assets | 3.7B | 3.6B | 3.5B | 3.4B | 3.0B |
Total Assets | 6.2B | 6.1B | 5.9B | 5.9B | 4.8B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 108.7M | 113.1M | 127.9M | 163.9M | 142.1M |
Short-term Debt | 31.1M | 29.7M | 26.6M | 22.7M | 21.7M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 2.0B | 2.1B | 1.9B | 1.9B | 1.3B |
Non-Current Liabilities | |||||
Long-term Debt | 88.2M | 97.0M | 100.3M | 102.7M | 64.4M |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 139.9M | 173.1M | 196.0M | 174.6M | 100.0M |
Total Non-Current Liabilities | 324.6M | 386.8M | 420.7M | 395.3M | 270.2M |
Total Liabilities | 2.4B | 2.5B | 2.3B | 2.3B | 1.6B |
Equity | |||||
Common Stock | 7.0K | 7.0K | 8.0K | 8.0K | 8.0K |
Retained Earnings | 2.5B | 2.4B | 2.6B | 2.6B | 2.2B |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 3.9B | 3.6B | 3.6B | 3.6B | 3.2B |
Key Metrics | |||||
Total Debt | 119.3M | 126.6M | 126.9M | 125.4M | 86.2M |
Working Capital | 454.4M | 380.0M | 498.5M | 570.0M | 523.9M |
Balance Sheet Composition
Align Technology Cash Flow Statement From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 421.4M | 445.1M | 361.6M | 772.0M | 1.8B |
Depreciation & Amortization | 145.0M | 142.4M | 125.8M | 108.7M | 93.5M |
Stock-Based Compensation | 173.7M | 154.0M | 133.4M | 114.3M | 98.4M |
Working Capital Changes | -209.4M | 4.6M | 96.8M | 107.9M | 111.5M |
Operating Cash Flow | 607.2M | 793.2M | 749.9M | 1.2B | 643.9M |
Investing Activities | |||||
Capital Expenditures | -115.6M | -177.7M | -291.9M | -401.1M | -154.9M |
Acquisitions | -183.4M | -77.0M | -12.3M | -8.0M | -420.8M |
Investment Purchases | 0 | -2.9M | -28.0M | -200.9M | -5.3M |
Investment Sales | 43.9M | 61.4M | 121.1M | 47.0M | 321.5M |
Investing Cash Flow | -254.9M | -195.9M | -213.3M | -563.4M | -231.5M |
Financing Activities | |||||
Share Repurchases | -352.9M | -592.4M | -435.0M | -375.0M | 0 |
Dividends Paid | - | - | - | - | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | - | 0 | 0 |
Financing Cash Flow | -355.7M | -598.3M | -501.7M | -458.3M | -30.8M |
Free Cash Flow | 622.7M | 608.1M | 276.8M | 771.4M | 507.3M |
Net Change in Cash | -3.5M | -1.0M | 34.9M | 147.8M | 381.6M |
Cash Flow Trend
Align Technology Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
25.27
Forward P/E
14.58
Price to Book
2.77
Price to Sales
2.73
PEG Ratio
0.73
Profitability Ratios
Profit Margin
11.04%
Operating Margin
16.10%
Return on Equity
11.41%
Return on Assets
6.50%
Financial Health
Current Ratio
1.23
Debt to Equity
3.14
Beta
1.61
Per Share Data
EPS (TTM)
$5.92
Book Value per Share
$53.98
Revenue per Share
$53.71
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
algn | 10.8B | 25.27 | 2.77 | 11.41% | 11.04% | 3.14 |
Intuitive Surgical | 168.4B | 65.35 | 9.44 | 16.04% | 28.51% | 0.00 |
Becton, Dickinson | 56.4B | 35.95 | 2.21 | 6.18% | 7.41% | 75.93 |
Alcon | 45.8B | 40.84 | 2.07 | 5.23% | 11.28% | 23.63 |
ResMed | 42.2B | 30.29 | 7.07 | 25.86% | 27.22% | 14.27 |
West Pharmaceutical | 17.8B | 37.05 | 6.08 | 17.72% | 16.48% | 10.52 |
Financial data is updated regularly. All figures are in the company's reporting currency.